# Efficacy and Safety of ATL-962 in Obese Diabetics

> **NCT00156897** · PHASE2 · COMPLETED · sponsor: **Alizyme** · enrollment: 600 (—)

## Conditions studied

- Non-Insulin-Dependent Diabetes Mellitus
- Obesity

## Interventions

- **DRUG:** ATL-962
- **DRUG:** Orlistat

## Key facts

- **NCT ID:** NCT00156897
- **Lead sponsor:** Alizyme
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 600 (—)
- **Last updated:** 2006-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00156897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00156897, "Efficacy and Safety of ATL-962 in Obese Diabetics". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00156897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*